Baker BROS. Advisors LP Increases Stake in Kymera Therapeutics, Inc. $KYMR

Baker BROS. Advisors LP raised its holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR) by 30.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 8,657,242 shares of the company’s stock after acquiring an additional 2,005,813 shares during the quarter. Kymera Therapeutics comprises 3.9% of Baker BROS. Advisors LP’s portfolio, making the stock its 8th largest position. Baker BROS. Advisors LP owned approximately 0.12% of Kymera Therapeutics worth $673,620,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of KYMR. Smartleaf Asset Management LLC boosted its stake in Kymera Therapeutics by 382.0% in the fourth quarter. Smartleaf Asset Management LLC now owns 535 shares of the company’s stock valued at $42,000 after acquiring an additional 424 shares during the last quarter. Larson Financial Group LLC boosted its stake in Kymera Therapeutics by 81.5% in the third quarter. Larson Financial Group LLC now owns 777 shares of the company’s stock valued at $44,000 after acquiring an additional 349 shares during the last quarter. Osaic Holdings Inc. boosted its stake in Kymera Therapeutics by 18,050.0% in the second quarter. Osaic Holdings Inc. now owns 1,089 shares of the company’s stock valued at $48,000 after acquiring an additional 1,083 shares during the last quarter. Caitong International Asset Management Co. Ltd bought a new position in Kymera Therapeutics in the fourth quarter valued at approximately $63,000. Finally, Raymond James Financial Inc. bought a new position in Kymera Therapeutics in the second quarter valued at approximately $73,000.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the stock. Piper Sandler raised their price objective on shares of Kymera Therapeutics from $125.00 to $140.00 and gave the company an “overweight” rating in a research note on Thursday, February 26th. Loop Capital set a $97.00 price objective on shares of Kymera Therapeutics in a research note on Monday, June 8th. Citigroup lifted their price target on shares of Kymera Therapeutics from $110.00 to $120.00 and gave the stock a “buy” rating in a research report on Monday, March 2nd. UBS Group lifted their price target on shares of Kymera Therapeutics from $90.00 to $128.00 and gave the stock a “buy” rating in a research report on Tuesday, March 3rd. Finally, Royal Bank Of Canada reissued an “outperform” rating and set a $108.00 price target on shares of Kymera Therapeutics in a research report on Thursday, February 26th. One research analyst has rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $117.14.

Insider Activity at Kymera Therapeutics

In related news, insider Noah Goodman sold 8,264 shares of the business’s stock in a transaction on Thursday, April 9th. The shares were sold at an average price of $87.50, for a total value of $723,100.00. Following the sale, the insider directly owned 53,542 shares of the company’s stock, valued at approximately $4,684,925. The trade was a 13.37% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Bruce Booth sold 5,900 shares of the business’s stock in a transaction on Wednesday, April 22nd. The shares were sold at an average price of $89.96, for a total transaction of $530,764.00. Following the completion of the sale, the director directly owned 5,641 shares in the company, valued at $507,464.36. This represents a 51.12% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 234,357 shares of company stock valued at $19,072,496. 15.98% of the stock is owned by corporate insiders.

Kymera Therapeutics Stock Up 2.8%

Shares of NASDAQ KYMR opened at $89.90 on Thursday. The company’s fifty day moving average is $82.99 and its 200-day moving average is $80.75. The stock has a market cap of $7.40 billion, a price-to-earnings ratio of -25.18 and a beta of 2.02. Kymera Therapeutics, Inc. has a twelve month low of $36.65 and a twelve month high of $103.00.

Kymera Therapeutics (NASDAQ:KYMR) last announced its quarterly earnings results on Thursday, April 30th. The company reported ($0.71) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.89) by $0.18. The company had revenue of $34.37 million for the quarter, compared to analysts’ expectations of $8.27 million. Kymera Therapeutics had a negative net margin of 611.94% and a negative return on equity of 24.71%. The business’s quarterly revenue was up 55.5% compared to the same quarter last year. During the same period last year, the firm posted ($0.82) earnings per share. On average, research analysts anticipate that Kymera Therapeutics, Inc. will post -3.25 EPS for the current fiscal year.

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.